aTyr Pharma is a biotherapeutics company focused on discovering and developing medicines based on novel immunological pathways. Their lead candidate, efzofitimod, is in Phase II clinical trials for pulmonary sarcoidosis and Phase 1b/2a trials for other interstitial lung diseases. They are also developing ATYR2810, a monoclonal antibody for solid tumors. They have a collaboration and license agreement with Kyorin Pharmaceutical for efzofitimod in Japan. Founded in 2005, aTyr Pharma is headquartered in San Diego, California.